The neohemocytes described in this report average approximately 0.4 microns in diameter. The microcapsule membrane is composed of biodegradable lipids, including phospholipids, and has a structure similar to liposomes. In a suspension having an apparent hematocrit of 0.5, the neohemocytes occupy 50% of the volume, the neohemocyte membrane accounts for approximately 2%, and the hemoglobin suspension accounts for about 48% of the volume. The encapsulated hemoglobin suspension averages 15.8g%. The P50 averages 26, the Hill Number averages 2.1, and methemoglobin is typically less than 5%. Transfusions in rats of neohemocyte suspensions, where the RBC hematocrit is lowered below 0.03, consistently give a fivefold-or-better increase in survival time relative to transfusions of equal concentrations of unencapsulated hemoglobin. Many of the problems of hemoglobin microencapsulation have been overcome, and the results strongly indicate that neohemocytes may become the functional component of a resuscitative fluid for use in man.
本报告中描述的新血细胞直径平均约为0.4微米。微胶囊膜由可生物降解的脂质组成，包括磷脂，其结构类似于脂质体。在表观血细胞比容为0.5的悬浮液中，新血细胞占体积的50%，新血细胞膜约占2%，血红蛋白悬浮液约占体积的48%。封装的血红蛋白悬浮液平均为15.8g%。P50平均为26，希尔系数平均为2.1，高铁血红蛋白通常低于5%。在大鼠中输注新血细胞悬浮液（红细胞血细胞比容降至0.03以下），相对于输注等浓度的未封装血红蛋白，其存活时间持续延长五倍或更多。血红蛋白微囊化的许多问题已得到解决，结果有力地表明，新血细胞可能成为用于人类的复苏液的功能成分。
